Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations
Lancet Rheumatol 2025;7:e505–18 Doi: 10.1016/S2665-9913(25)00063-3
This systematic review highlighted the major gaps in evidence regarding rare SLE manifestations, with many findings dependent on variable methodologies or single reports. Arnard et al. established an international consensus on therapeutic strategies for rare SLE manifestations.
Keywords:
BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis
Ann Rheum Dis 2025;0:1−9
Hu et al. report that anti-BCMA only CAR T cell can help LN patients safely and effectively, indicating its potential to be a feasible therapeutic strategy in treating autoimmune diseases with abnormal humoral immune responses.
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases
Lancet Rheumatol, 2025. Epub ahead of print
Carter et al. review the clinical and mechanistic development of B-cell targeted therapies over the last two decades in autoimmune rheumatic diseases. B-cell depletion depth, repopulation dynamics, and immunogenicity determine long-term efficacy and inform the rationale for emerging
dual-targeted approaches, particularly in systemic lupus erythematosus where belimumab and rituximab combinations show potential to mitigate relapse driven by BAFF.
Opportunities and limitations of B bell depletion approaches in SLE
Nature Review Rheumatol, 2025;21:111–126 DOI: 10.1038/s41584-024-01210-9
Stockfelt et al. reviewed the long-term efficacy and challenges of B cell depletion strategies in SLE. Rituximab, a CD20-targeting monoclonal antibody, has demonstrated efficacy in a subset of patients but remains limited by immunogenicity, residual B cells, and B-cell activating factor (BAFF)-mediated relapse. Newer strategies incorporating CAR T cells, bispecific T cell engagers, and combination therapies aim to enhance B cell depletion and optimise outcomes.
Keywords:
The 2024 APLAR consensus on the management of lupus nephritis
International Journal of Rheumatic Diseases; 28:e70021 DOI: 10.1111/1756-185X.70021
Mok et al. provided updated consensus recommendations from APLAR, emphasising evidence-based guidance for managing lupus nephritis in Asian populations. These recommendations consider ethnic, socioeconomic, and pharmacogenetic factors, focusing on treatment regimens, adjunctive therapies, and patient-specific approaches to optimise outcomes.
Emerging Immunotherapeutic Strategies for Cutaneous Lupus Erythematosus: An Overview of Recent Phase 2 and 3 Clinical Trials
Expert Opin Emerg Drugs 2023;28(4):257–73 DOI: 10.1080/14728214.2023.2273536
Current treatments for refractory CLE are insufficient, often leading to suboptimal disease control, and demanding escalated therapies associated with systemic toxicities. However, recent Phase 2 & 3 trials offer promising results, suggesting new therapeutics approved for CLE are on the horizon.